AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis

AB Science SA presented the advances of masitinib to treat progressive forms of multiple sclerosis at the ECTRIMS 2024 conference. Based on the MAXIMS study, this development focuses on patients with primary progressive and non-active secondary progressive multiple sclerosis.

The results show that masitinib significantly reduces disability progression, with notable improvements in manual dexterity and decreased neuronal damage. Compared with tolebrutinib, another microglia-targeted treatment, masitinib presents a credible alternative with an acceptable safety profile without increased hepatic or infection risks.

Professor Patrick Vermersch highlights the potential of masitinib as a serious alternative to BTK inhibitors for patients suffering from progressive multiple sclerosis. This advance supports AB Science's strategy of developing treatments for unmet medical needs.